RABV

Rabies Virus

The Rabies Virus (RABV) is a member of the Lyssavirus genus within the Rhabdoviridae family, belonging to the order Mononegavirales. This virus is a negative-stranded RNA virus that causes rabies, a fatal neurological disease transmitted primarily through animal bites. The virus's primary function involves infecting neurons, leading to severe neurological symptoms such as hydrophobia and paralysis. One of the known receptors of RABV, nAchR, is restricted to muscle cells, evidence for primary infections of muscle cells followed by transmission to neurons. It is thought that RABV entry into primary motor neurons is followed by retrograde axonal transport, replication and assembly in the neuronal cell body, and then transport to and budding from another synapse to start a new round of infection and resultant neuron-to-neuron spread. Rabies is a significant public health concern, particularly in Asia and Africa, where the disease burden is highest. Effective prevention relies on vaccination, which can provide protection against rabies virus but may not offer cross-protection against other lyssaviruses^[1].

References:

[1]. Davis BM, et al. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol. 2015 Nov;2(1):451-71. [Content Brief]

RABV Inhibitors (6)

RABV Related Products (14):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-18980

Rottlerin	Inhibitor	98.39%
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation. Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection.

HY-P5623A1

RVG-Cys acetate		99.78%
RVG-Cys (RVG29-Cys;RDP-Cy) acetate is based on rabies virus glycoprotein (RVG29) peptide and connected to Cys to facilitate subsequent coupling.

HY-P4086

Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)		98.00%
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction.

HY-P5623A

RVG-Cys		99.61%
RVG-Cys (RVG29-Cys) is based on rabies virus glycoprotein (RVG29) peptide and connected to Cys to facilitate subsequent coupling.

HY-133735A

GRP-60367 hydrochloride	Inhibitor	99.41%
GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein.

HY-P0285

Rabies Virus Glycoprotein		99.69%
Rabies Virus Glycoprotein is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.

HY-P0285A

Rabies Virus Glycoprotein TFA		98.32%
Rabies Virus Glycoprotein (TFA) is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.

HY-P99624

Foravirumab
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III.

HY-P99811

Rafivirumab	Inhibitor
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails.

HY-133735

GRP-60367	Inhibitor
GRP-60367 is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains.

HY-P99856

Docaravimab	Inhibitor
Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies.

HY-P99513

Zamerovimab
Zamerovimab (CTB011) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Zamerovimab targets residues at and near antigenic site III. Zamerovimab can be used in rabies studies.

HY-P99727

Mazorelvimab	Inhibitor
Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies.

HY-P99792

Ormutivimab
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.

Name
Email *

	Sorry, but the email address you supplied was invalid.